54 results on '"Gold K"'
Search Results
2. HCN and HCO+ in Planetary Nebulae: The Next Level
3. Assessment of QoI and CAA fungicide resistance of Plasmopara viticola populations in vineyards of the Great Lakes region in the United States of America
4. OA03.04 Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
5. P19.10 Evaluation of Local Therapy for Oligoprogressive Disease in Metastatic NSCLC Patients on Immunotherapy
6. LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
7. 975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma
8. P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
9. Parents’ and healthcare professionals’ experiences of care after stillbirth in low‐ and middle‐income countries: a systematic review and meta‐summary
10. Making stillbirths visible: a systematic review of globally reported causes of stillbirth
11. Who tells a mother her baby has died? Communication and staff presence during stillbirth delivery and early infant death
12. Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial
13. Patient or Clinician: Duration of Use of Intrauterine Devices Based on Who Initiated Discussion of Placement
14. 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
15. Maternal complications associated with stillbirth delivery: A cross-sectional analysis
16. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study
17. Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses
18. Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases
19. Alk Inhibitor Ap26113 in Patients with Advanced Malignancies, Including Alk+ Non-Small Cell Lung Cancer (Nsclc): Updated Efficacy and Safety Data
20. Impact of Chemotherapy Response and Radiation Dose on Overall Survival in Patients With Inoperable Non-small Cell Lung Cancer Treated With Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy
21. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center
22. Lectures
23. Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC).
24. Biologic risk model development for recurrent and second primary tumors (SPTs) in patients (pts) with early stage non-small cell lung cancer (ES NSCLC).
25. Non-Oral Poster 24
26. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)
27. Manual of Seed Handling in Genebanks by N. Kameswara Rao, Jean Hanson, M. Ehsan Dulloo, Kakoli Ghosh, David Nowell & Michael Larinde. xiv+147 pp. Rome, Italy: Bioversity International (2006). ISBN 978-92-9043-740-6
28. Genomic copy number alterations in non-small cell lung cancers identified using CBS and MSA
29. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma
30. Navigating care after a baby dies: a systematic review of parent experiences with health providers
31. Cognitive/behavioral approaches
32. PMD6 MODIFYING COST-EFFECTIVENESS RATIOS TO BE MAXIMALLY COMPARABLE ACROSS MULTIPLE DISEASES:AN APPLICATION OF MANIFOLD THEORY
33. PCN18: COLORECTAL CANCER SCREENING: AWARENESS, UTILIZATION, AND BARRIERS
34. PCN19: COLORECTAL CANCER SCREENING TESTS: VARIATION IN PREFERENCES BASED ON GENDER AND RACE
35. Role of planktonic protozoa in the marine food chain. Seasonal changes, relative abundance, and cell size distribution of Tintinnida. Progress report, May 1, 1973--April 30, 1974
36. Accumulation and transport of minerals by marine protozoa. Progress report, September 1, 1976--November 30, 1977. [Mineral concentration by Tintinnida in coastal waters]
37. Accumulation and transport of minerals by marine protozoa. Progress report, September 1, 1975--August 31, 1976
38. Role of planktonic protozoa in the marine food chain. The distribution and abundance of Tintinnida in temperate neritic habitats. Progress report, September 1, 1972--August 31, 1975
39. Accumulation and transport of minerals by marine protozoa. Final report, September 1, 1975--November 30, 1978. [Ultrastructural studies of cultures of Tintinnopsis power]
40. Role of planktonic protozoa in the marine food chain. Seasonal changes, relative abundance, and cell size distribution of Tintinnida. Progress report, May 1, 1972--April 30, 1973
41. ROLE OF PLANKTONIC PROTOZOA IN THE MARINE FOOD CHAIN. Progress Report, June 1, 1969--April 30, 1972.
42. GROWTH CHARACTERISTICS OF TINTINNIDA IN CONTINUOUS CULTURE.
43. Serendipity in Diagnostic Imaging: Magnetic Resonance Imaging of the Breast
44. The costs and effects of cervical and breast cancer screening in a public hospital emergency room. The Cancer Control Center of Harlem.
45. Ciliate feeding: effect of food presence or absence on occurrence of striae in tintinnids
46. Some observations on the green planktonic alga, Botryococcus braunii and its bloom form
47. Variability in the Calcium Phosphate Concretion Load in the Kidney of Mercenaria mercenaria
48. Long-term follow-up after coronary artery bypass
49. CT diagnosis of circumcaval ureter
50. Relationship between multicentric reticulohistiocytosis and tuberculosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.